Over the past two decades the treatment landscape for non-Hodgkin lymphoma (NHL) has rapidly evolved, with the development of Bruton’s tyrosine kinase (BTK) inhibitors making a particularly significant impact and opening the door to the possibility of chemotherapy-free regimens. In 2013, ibrutinib became the first BTK inhibitor to receive FDA approval for the treatment of follicular lymphoma, followed by approvals for Waldenström’s macroglobulinemia and marginal zone lymphoma in 2015 and 2017 respectively. Since then, the BTK inhibitors acalabrutinib and zanubrutinib have received FDA approval and many trials are exploring novel BTK inhibitors and combinations.

In today’s episode, Thomas Witzig, of the Mayo Clinic Rochester, Rochester, MN, Chan Yoon Cheah, of the Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, Gilles Salles of the Memorial Sloan Kettering Cancer Center, New York City, NY, and Paolo Ghia of Università Vita-Salute San Raffaele, Milan, Italy, talk on the latest data from key clinical trials of BTK inhibitors for the treatment of NHL.

The post Novel BTK inhibitors for NHL appeared first on VJHemOnc.